Alturas Analytics
Maggie McMullen has a diverse background in business development and sales within the pharmaceutical and biotechnology industries. Maggie started their career as a Territory Account Manager at XenoTech LLC in 2000 and later became a Staff Scientist in the enzyme induction department.
In 2006, Maggie transitioned to ProImmune as a Technical Sales Representative before returning to XenoTech LLC as an Executive Account Manager/Commercial Operations from 2007 to 2013. During this time, they also managed the North American based Account Management team.
From 2014 to 2015, Maggie held positions as a Business Development Manager at Frontage Laboratories and Coté Orphan LLC. Maggie then served as the Director of Business Development at Qualyst Transporter Solutions from 2015 to 2018.
From 2016 to 2022, Maggie was a Business Development Advisor at RareMoon | Orphan Product Development. Maggie then joined Lovelace Biomedical as a Business Development Operations Manager before being promoted to Business Development Operations Director in 2022.
Currently, Maggie holds the position of Chief Business Development Officer at Alturas Analytics Inc., a Contract Research Organization specializing in preclinical and clinical bioanalysis.
Throughout their career, Maggie has demonstrated expertise in building client relationships, increasing sales, and providing expert solutions to meet unique bioanalytical needs.
Maggie McMullen obtained a Bachelor's degree in Zoology from the University of Wisconsin-Madison from 1992 to 1996. Maggie also completed a program at the American Management Association from 2011 to 2012, although no degree or field of study information was provided.
This person is not in any offices
Alturas Analytics
At Alturas Analytics, we deliver results on time with the highest level of integrity. Our business is built on developing long term collaborations with our clients by providing advanced MS/MS solutions through a focused emphasis on teamwork, communication and exceptional science. Alturas has a proven record with complex analysis supporting drug candidates for the pharmaceutical and biotechnology industries, from discovery through phase IV clinical trials. The company operates in a GLP environment using validated operational processes in strict adherence to internal SOPs and applicable global regulations. Bioanalytical services routinely performed include the following: • GC-MS/MS and LC-MS/MS bioanalysis – allows for the broadest range of chemical properties across a wide mass range • GLP and non-GLP bioanalysis of large and small molecules in any matrix • Quantitative Antibody Drug Conjugates (ADC) analysis • Biomarker quantitation • Protein binding estimations • Dried Blood (DBS) and Matrix Spot (DMS) analysis (limited sample volume ex. pediatrics, CSF, tears) Ensuring that a project is completed on time to a company's specifications demands clear lines of communication before, during, and after a study's completion. Clients have direct access to a team of professionals who understand the critical nature of the business. An Alturas Study Director is assigned to each client based on their working knowledge with compounds of similar chemical properties. Comments & Feedback: "Thanks. We owe a lot to Alturas for the great nonclinical and clinical bioanalytical support for the program. Happy 2013!" January 2013: Comment from a Sponsor after receiving FDA Approval. “You solved all of our bioanalytical problems.” Comment from a Sponsor after the Alturas Team was able to address technical difficulties. "Five Stars. Would definitely use Alturas again for upcoming projects." Comment from a Sponsor in 2016.